ÂÜÀòÂÒÂ×

Karl Rothweiler has extensive experience in the pharmaceutical and biotechnology industry. Karl began their career in 1995 as the Founder of Entity Holding, where they worked until 2004. In 2004, they founded Aglaia Oncology Funds and took on the role of Managing Partner. Continuing their entrepreneurial ventures, Karl went on to found and serve as a Founding Investor and Member of the Supervisory Board for various companies including Merus N.V., ORCA Therapeutics, Syntarga, and Modra Pharmaceuticals. In 2006, they founded InteRNA Technologies BV and held the positions of Founder, Founding Investor, and Member of the Supervisory Board until April 2023. From 2004 to 2017, they also acted as Founder, Founding Investor, and Member of the Supervisory Board for ISA Pharmaceuticals. In 2016, they founded Sapreme Technologies BV and assumed the roles of Founder, Founding Investor, and Member of the Supervisory Board. Most recently, in 2022, Karl became a Founding Investor and Member of the Supervisory Board for Inthera Bioscience AG. Throughout their career, Karl has consistently demonstrated their entrepreneurial spirit and expertise in the field of pharmaceuticals and biotechnology.

Karl Rothweiler's education history begins with their attendance at Fioretti College from 1972 to 1979. Karl then pursued a Bachelor of Business Administration (BBA) degree at Nyenrode New Business School from 1979 to 1982. Following this, they pursued a Master of Business Administration (MBA) degree with a field of study in Business at The University of Georgia from 1982 to 1983. Beyond these educational experiences, there is no further information available.